Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th Internation...
October 05 2017 - 4:30PM
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company
committed to developing medicines for patients with rare
neurological diseases, today announced that it will provide a
poster presentation of preclinical data on OV101, an
investigational drug in development for treatment of
neurodevelopmental symptoms characteristic of disorders such as
Angelman syndrome and Fragile X syndrome, at the 18th International
Fragile X and Related Neurodevelopmental Disorders Workshop taking
place October 12-16, 2017, in Saint-Alexis-des-Monts, Quebec.
Details of the poster presentation are listed below.
Title: Gaboxadol normalizes behavioral
abnormalities in a mouse model of Fragile X
SyndromePresenter: Brett Abrahams, Ph.D., director
and head of pre-clinical biology, Ovid
TherapeuticsTime: Sunday, October 15, 2017, 5:00
p.m. – 7:00 p.m. ESTLocation: Hôtel Sacacomie,
Saint-Alexis-des-Monts, Quebec
About OV101
OV101 (gaboxadol) is believed to be the only delta (δ)-selective
GABAA receptor agonist in development and the first investigational
drug to specifically target the disruption of tonic inhibition that
is thought to be the underlying cause of certain neurodevelopmental
disorders. OV101 has been demonstrated in laboratory studies and
animal models to selectively activate the δ-subunit of GABAA
receptors, which are found in the extrasynaptic space (outside of
the synapse), and thereby impact neuronal activity through tonic
inhibition.
Ovid is developing OV101 for the treatment of Angelman syndrome
and Fragile X syndrome to potentially restore tonic inhibition and
relieve several of the symptoms of these disorders. In preclinical
studies, it was observed that OV101 improved symptoms of Angelman
syndrome and Fragile X syndrome.
In September 2016, the FDA granted orphan drug designation for
OV101 for the treatment of Angelman syndrome. The United States
Patent and Trademark Office has granted Ovid two patents directed
to methods of treating Angelman syndrome using OV101. The issued
patents expire in 2035, without regulatory extensions.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based
biopharmaceutical company using its BoldMedicine™ approach to
develop therapies that transform the lives of patients with rare
neurological disorders. Ovid’s drug candidate, OV101, is currently
in development for the treatment of Angelman syndrome and Fragile X
syndrome. Ovid has initiated the Phase 2 STARS trial of OV101 in
adults with Angelman syndrome and a Phase 1 trial in adolescents
with Angelman syndrome or Fragile X syndrome. Ovid is also
developing OV935 in collaboration with Takeda Pharmaceutical
Company Limited for the treatment of rare epileptic
encephalopathies and has initiated a Phase 1b/2a trial of
OV935.
For more information on Ovid, please visit
http://www.ovidrx.com/.
Forward-Looking StatementsThis press release
includes certain disclosures that contain
“forward-looking statements,” including, without limitation,
statements regarding progress, timing, scope and results of
clinical trials for Ovid’s product candidates, the reporting of
clinical data regarding Ovid’s product candidates, and the
potential use of TAK-935/OV935 to treat rare
epilepsies. You can identify forward-looking statements
because they contain words such as “will,” “believes” and
“expects.” Forward-looking statements are based on Ovid’s current
expectations and assumptions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that may differ materially from
those contemplated by the forward-looking statements, which are
neither statements of historical fact nor guarantees or assurances
of future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements are set forth in Ovid’s filings with the Securities and
Exchange Commission, including its Quarterly Report on Form
10-Q for the quarter ended June 30, 2017, under the caption
“Risk Factors.” Ovid assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes
available.
Ovid Contacts:Investors:Burns McClellanSteve
Klass, 212-213-0006Sklass@burnsmc.com
Media:Pure Communications, Inc.Katie Engleman,
910-509-3977katie@purecommunicationsinc.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024